Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults
Adam J. Lamble(Seattle Children's Hospital), Shannon L. Maude(Children's Hospital of Philadelphia), Nirali N. Shah(National Institutes of Health), Emily M. Hsieh(Children's Hospital of Los Angeles), Liora M. Schultz(Stanford Medicine), Sara Ghorashian(Great Ormond Street Hospital), Rebecca Gardner(Seattle Children's Hospital), Rayne H. Rouce(Baylor College of Medicine), Khanh Nguyen(Stanford University), Kevin O. McNerney(Children's Hospital of Philadelphia)
Cited by 32
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k